Transfusion
Making blood transfusions safe
For over 40 years, our Transfusion product line has played a vital role in making blood transfusions safe. We develop, manufacture, and support a complete line of immunohematology reagents, automated test systems, and data management software used by hospitals, clinical reference laboratories, and blood donor centers to find the right match for a patient in need of a life-saving blood transfusion. We’ve developed an expertise in blood bank automation technology that is unmatched in our industry. The core values we’ve brought to this process – innovation, productivity, and partnership – have made us one of the world’s leading transfusion diagnostics companies.
Advancing blood bank automation and diagnostics
Blood is vital to life. Every few seconds, a patient needs blood. Blood transfusions are critical to support trauma patients, surgeries, and cancer treatments. Multiple transfused patients include those with genetic blood disorders such as sickle cell disease and thalassemia. To support patients in need of a blood transfusion, diagnostic testing to characterize the patient’s blood and available donor units is essential. Hospitals, donor centers, and reference laboratories rely on our products for blood typing, antibody screening, and identification of red blood cells and platelets, as well as complex antibody workups.
Improving donor-recipient compatibility for blood transfusions
We provide results-oriented and efficiency-focused immunohematology laboratories and blood donor centers with total solutions to improve patient care and safety. Our products ensure the best donor-recipient compatibility for a life-saving blood transfusion with our manual and automated reagents, unique specialty products, and scalable automation. Paired with our industry-leading data management, our solutions deliver test results accurately, efficiently, and productively.
Transfusion in 2023
Investing in future growth
2023 marked Werfen’s acquisition of Immucor and our Transfusion leadership team focused heavily on early integration initiatives throughout the year. We were able to retain key talent in our organization and we will leverage more benefits from the integration in 2024.
We continue to invest in new innovations to advance the field of transfusion compatibility, including menu growth for our fully automated systems and enhanced data management capabilities. We were thrilled to commercialize our new ImmuLINK Panel ID software, which is an automated antibody identification software. This product launch solidifies our focus and investment on digital transformation for the immunohematology laboratory.
Across the diagnostics industry, there is a heavy focus on new IVDR guidelines and this was a key area for our Transfusion technology center in 2023. We are proud to report that we met 100% of our Class D certificate targets for 2023. We have approximately 30% of our remaining Class D certificates in notified body review, with just 2% pending submission. This represents 20% of the total IVD Class D products certified in the market.
We are constantly improving our supply chain efforts to strengthen our relationships with key strategic partners. This is essential in supporting our global customers in the critical work they perform to support their patients. We remain vigilant in reducing risk within our supply chain.
Finally, we remain committed to furthering professional excellence and enhancing patient care by making investments in technical education and support to the blood bank industry. In 2023 we executed hundreds of global educational events, including over 40 in-person Education Days, User Group Meetings and Wet Workshops, and over 20 global webinar programs. This educational role brings value to our industry and we will continue to partner with our customers to build the future leaders of immunohematology.